Abstract
The targeted treatment of advanced non-small cell lung cancer (NSCLC) harboring genomic rearrangement of ALK is a paradigm for personalized oncology. ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
